Menu
Fechar
HRS4R
Vull donar

YOLANDA GONZALEZ MONTES

Hematologia
Firma
YOLANDA GONZALEZ-MONTES
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1
Projectes
Publicacions

Projectes

Hematologia

Ajuts per donar suport a les activitats dels grups de recerca de Catalunya (SGR-Cat 2021) - Hematologia

Codi oficial: 6822ZB3KJ Data inici: 01/01/2022 Data fi: 31/12/2024 Investigador/a principal: DAVID GALLARDO GIRALT Organisme finançador: AGENCIA DE GESTIO D'AJUTS UNIV. I RECER. Ajuda: 0 €

Publicacions

Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105
Rosiñol L, Oriol A, Ríos-Tamayo R, Blanchard MJ, Jarque I, Bargay J, Hernandez Garcia MT, Cabañas V, Carrillo-Cruz E, Sureda A, Martinez-Lopez J, Krsnik I, Gonzalez ME, Casado Montero LF, Marti JM, Encinas C, de Arriba F, Palomera L, Sampol A, Gonzalez-Montes Y, Cabezudo E, Paiva B, Puig N, Cedena MT, de la Cruz J, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé J

LENALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT IXAZOMIB MAINTENANCE TAILORED BY RESIDUAL DISEASE STATUS IN MYELOMA.

Blood, 2023, 142, 1518-1528 dx.doi.org/10.1182/blood.2022019531
Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

BLOOD CANCER JOURNAL, 2022, 12, 9-9 dx.doi.org/10.1038/s41408-021-00593-2
Ocio EM, Montes-Gaisán C, Bustamante G, Garzón S, González E, Pérez E, Sirvent M, Arguiñano JM, González Y, Ríos R, de Miguel D, Grande M, Fernández A, Naves A, Rosiñol L

Clinical and Sociodemographic Characteristics of Patients With Relapsed and/or Refractory Multiple Myeloma and Their influence on Treatment in the Real-World Setting in Spain: The CharisMMa Study.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 241-249 dx.doi.org/10.1016/j.clml.2021.10.001
Moreno DF, Clapés V, Soler JA, González-Montes Y, Gironella M, Motlló C, Granell M, Abella E, García-Pintos M, García-Guiñón A, Cabezudo E, Bladé J, Rosiñol L

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 635-642 dx.doi.org/10.1016/j.clml.2022.04.014
Tamariz-Amador LE, Rodríguez-Otero P, Jiménez-Ubieto A, Rosiñol L, Oriol A, Ríos R, Sureda A, Blanchard MJ, Hernández MT, Cabañas Perianes V, Jarque I, Bargay J, Gironella M, De Arriba F, Palomera L, Gonzalez-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, Casado LF, González-Rodriguez AP, López-Anglada L, Puig N, Cedena MT, Paiva B, Mateos MV, San-Miguel J, Lahuerta JJ, Bladé J, Trocóniz IF

Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22, 844-852 dx.doi.org/10.1016/j.clml.2022.04.024
Encinas C, Hernandez-Rivas JÁ, Oriol A, Rosiñol L, Blanchard MJ, Bellón JM, García-Sanz R, de la Rubia J, de la Guía AL, Jímenez-Ubieto A, Jarque I, Iñigo B, Dourdil V, de Arriba F, Pérez-Ávila CC, Gonzalez Y, Hernández MT, Bargay J, Granell M, Rodríguez-Otero P, Silvent M, Cabrera C, Rios R, Alegre A, Gironella M, Gonzalez MS, Sureda A, Sampol A, Ocio EM, Krsnik I, García A, García-Mateo A, Soler JA, Martín J, Arguiñano JM, Mateos MV, Bladé J, San-Miguel JF, Lahuerta JJ, Martínez-López J, GEM/PETHEMA (Grupo Español de Mieloma/Programa para el Estudio de la Terapéutica

A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma.

BLOOD CANCER JOURNAL, 2022, 12, 68-68 dx.doi.org/10.1038/s41408-022-00652-2
Chang-Chan DY, Ríos-Tamayo R, Rodríguez Barranco M, Redondo-Sánchez D, González Y, Marcos-Gragera R, Sánchez MJ

Trends of incidence, mortality and survival of multiple myeloma in Spain. A twenty-three-year population-based study

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021, 23, 1429-1439 dx.doi.org/10.1007/s12094-020-02541-1
Cejalvo MJ, Bustamante G, González E, Vázquez-Álvarez J, García R, Ramírez-Payer Á, Pérez-Persona E, Abella E, Garzón S, García A, Jarque I, González MS, Sampol A, Motlló C, Martí JM, Alcalá M, Duro R, González Y, Sastre JL, Sarrà J, Lostaunau G, López R, de la Rubia J

Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma

ANNALS OF HEMATOLOGY, 2021, 100, 1769-1778 dx.doi.org/10.1007/s00277-021-04529-5
Rosiñol L, Oriol A, Rios R, Sureda A, Blanchard MJ, Hernández MT, Martínez-Martínez R, Moraleda JM, Jarque I, Bargay J, Gironella M, de Arriba F, Palomera L, González-Montes Y, Martí JM, Krsnik I, Arguiñano JM, González ME, González AP, Casado LF, López-Anglada L, Paiva B, Mateos MV, San Miguel JF, Lahuerta JJ, Bladé J

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Blood, 2019, 134, 1337-1345 dx.doi.org/10.1182/blood.2019000241

Formulari de contacte

Coneix l’IDIBGI!

 menu